Publication:
Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.

dc.contributor.authorFlores-López, María
dc.contributor.authorGarcía-Marchena, Nuria
dc.contributor.authorAraos, Pedro
dc.contributor.authorRequena-Ocaña, Nerea
dc.contributor.authorPorras-Perales, Oscar
dc.contributor.authorTorres-Galván, Sandra
dc.contributor.authorSuarez, Juan
dc.contributor.authorPizarro, Nieves
dc.contributor.authorde la Torre, Rafael
dc.contributor.authorRubio, Gabriel
dc.contributor.authorRuiz-Ruiz, Juan Jesús
dc.contributor.authorRodríguez de Fonseca, Fernando
dc.contributor.authorSerrano, Antonia
dc.contributor.authorPavón-Morón, Francisco Javier
dc.date.accessioned2023-05-03T13:49:11Z
dc.date.available2023-05-03T13:49:11Z
dc.date.issued2022-04-30
dc.description.abstractPreclinical evidence suggests a main role of lysophosphatidic acid (LPA) signaling in drug addiction. Recently, we reported alterations in the plasma concentrations of LPA species in patients with alcohol use disorder (AUD). As there are sex differences in drug addiction, the main aim of the present study was to investigate whether relevant LPA species (16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA) were associated with sex and/or substance use disorder (SUD). This exploratory study was conducted in 214 abstinent patients with lifetime SUD, and 91 healthy control subjects. The SUD group was divided according to the diagnosis of AUD and/or cocaine use disorder (CUD). Participants were clinically assessed, and plasma samples were collected to determine LPA species and total LPA. We found that LPA concentrations were significantly affected by sex, and women showed higher concentrations than men. In addition, there were significantly lower 16:0-LPA, 18:2-LPA and total LPA concentrations in patients with SUD than in controls. Namely, patients with CUD and AUD + CUD showed lower LPA concentrations than controls or patients with AUD. In conclusion, our data suggest that LPA species could be potential biomarkers for SUD in women and men, which could contribute to a better stratification of these patients in treatment programs.
dc.identifier.doi10.3390/brainsci12050588
dc.identifier.issn2076-3425
dc.identifier.pmcPMC9139721
dc.identifier.pmid35624975
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139721/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2076-3425/12/5/588/pdf?version=1652078034
dc.identifier.urihttp://hdl.handle.net/10668/20854
dc.issue.number5
dc.journal.titleBrain sciences
dc.journal.titleabbreviationBrain Sci
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectalcohol
dc.subjectbiomarker
dc.subjectcocaine
dc.subjectlysophosphatidic acid
dc.subjectsex
dc.subjectsubstance use disorder
dc.titleSex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9139721.pdf
Size:
740.21 KB
Format:
Adobe Portable Document Format